Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Taxanes are an established option in the standard treatment paradigm for patients with metastatic breast cancer (MBC). Neuropathy is a common, dose-limiting side effect of taxane therapy that is often managed by dose reductions and delays. The severity, time to onset, and improvement in neuropathy are important considerations for patient management and vary among currently approved taxanes. The rate of grade ≥3 neuropathy with taxanes has been shown to be dose and schedule dependent; however, time to improvement to grade ≤1 is typically shorter for nab-paclitaxel than for other taxanes in patients with MBC. Many tools for assessing patient-reported neuropathy exist. Because MBC is incurable and patient quality of life must be critically considered when making treatment decisions, there is a need for more prospective trials to assess patient-reported neuropathy. Validated predictors of taxane-related neuropathy may play an important role in treatment decisions in the future. This review will focus on the toxicity profile (i.e., neuropathy) of each of the taxanes used in the treatment of MBC, will provide updates on tools used for the assessment of neuropathy, and will highlight newly discovered predictors of taxane-related neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other common symptoms among cancer patients (e.g., nausea, neuropathy, swelling of arms and legs, hot flashes, cognitive problems) have received less attention in the MBC literature [6, 12–14].”
From Symptom experiences in metastatic breast cancer patients: relationships to activity engagement, value-based living, and psychological inflexibility (2017) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081 · cited 1×
“[85] Metastatic or locally advanced, previously treated (346) Paclitaxel 90 mg/m(2) weekly for 3 of 4 weeks NR 17 <1”
BackgroundGradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153 · cited 1×
“[17] Metastatic, previously treated (229) nab-Paclitaxel 260 mg/m(2) q3w NR 10 0”
Dyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482
Smith, E. M. L., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., Bressler, L. R., Fadul, C. E., Knox, C., Le-Lindqwister, N., et al. (2013) · JAMA · doi:10.1001/jama.2013.2813 · Cited by 1,014
Chemotherapy-induced peripheral neuropathy
Quasthoff, S., & Hartung, H. P. (2002) · Journal of Neurology · doi:10.1007/pl00007853 · Cited by 966
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897 · cited 1×
“[84] Metastatic or locally advanced, previously treated (231) Docetaxel 100 mg/m(2) q3w NR 2 (grade 3 or higher)”
BackgroundAbbott, C. A., Malik, R. A., van Ross, E. R. E., Kulkarni, J., & Boulton, A. J. M. (2011) · Diabetes Care · doi:10.2337/dc11-1108 · Cited by 868
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756 · cited 1×
“With respect to taxane-based therapy, in an exploratory analysis of a phase III trial in patients with advanced non-small cell lung cancer, those with diabetes who were treated with nab-paclitaxel plus carboplatin had a 4 % higher rate of grade ≥3 peripheral neuropathy (7 %) than did the intent-to-treat population (3…”
Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., Gipson, G., Burstein, H., Lake, D., Shapiro, C. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6699 · Cited by 594 · cited 2×
“[29] Metastatic, previously treated (225) Paclitaxel 175 mg/m(2) q3w 21 12 0”
BackgroundPharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Research works printed but not linked: 1
- Hirsh V, Owen SP, Ko A, Renschler MF, Socinski MA (2013) nab-Paclitaxel in combination with carboplatin as first-line therapy in diabetic patients with advanced non-small cell lung cancer (NSCLC). In: 15th World conference on lung cancer, poster P1 10-044
Cited by
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
“Chemotherapy with taxanes often leads to neuropathy, which can persist long after treatment ends.(35) Anthracyclines and HER-2–targeted drugs can lead to cardiomyopathy and congestive heart failure.”
BackgroundCancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Seca, A., & Pinto, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010263 · Cited by 686
“Higher doses of nab-paclitaxel can be administered over a shorter infusion time, and consequently, there is an improvement in neuropathy side effects after the therapy discontinuation [57], although peripheral sensory neuropathy occurred more frequently with nab-paclitaxel compared to paclitaxel [55].”
BackgroundMetastatic and triple-negative breast cancer: challenges and treatment options
Al-Mahmood, S., Sapiezynski, J., Garbuzenko, O. B., & Minko, T. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0551-3 · Cited by 524
“anthracycline-resistant MBC cases [131, 132].”
BackgroundOptimizing the safety of antibody–drug conjugates for patients with solid tumours
Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00783-w · Cited by 269
Chemotherapy-induced peripheral neurotoxicity
Cavaletti, G., & Marmiroli, P. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000234 · Cited by 239
Neuropathic cancer pain: prevalence, pathophysiology, and management
Yoon, S. Y., & Oh, J. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.162 · Cited by 197
“CIPN symptoms include sensory loss, paresthesia, dysesthesia and pain, sometimes accompanied by muscle weakness [16,24-26].”
BackgroundChemotherapeutic agents for the treatment of metastatic breast cancer: An update
Abotaleb, M., Kubatka, P., Caprnda, M., Varghese, E., Zolakova, B., Zubor, P., Opatrilova, R., Kruzliak, P., Stefanicka, P., & Büsselberg, D. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.108 · Cited by 184
Robijns, J., Nair, R. G., Lodewijckx, J., Arany, P., Barasch, A., Bjordal, J. M., Bossi, P., Chilles, A., Corby, P. M., Epstein, J. B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.927685 · Cited by 175
Nardo, P. D., Lisanti, C., Garutti, M., Buriolla, S., Alberti, M., Mazzeo, R., & Puglisi, F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2151584 · Cited by 185
“the individual antineoplastic drug [75,78,79]; it results in”
BackgroundTaxane-Induced Peripheral Neurotoxicity
Velasco, R., & Bruna, J. (2015) · Toxics · doi:10.3390/toxics3020152 · Cited by 149
“The incidence of all grades of TIPN among those patients treated with paclitaxel is high, ranging from 57%–83% overall and with severity in 2%–33% of patients [12].”
BackgroundMamounas, E. P., Untch, M., Mano, M. S., Huang, C., Geyer, C. E., von Minckwitz, G., Wolmark, N., Pivot, X. B., Küemmel, S., DiGiovanna, M. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.04.011 · Cited by 150
Chemotherapy-Related Neurotoxicity
Taillibert, S., Rhun, É. L., & Chamberlain, M. C. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0686-x · Cited by 133
Talib, W. H., Alsalahat, I., Daoud, S., Abutayeh, R. F., & Mahmod, A. I. (2020) · Molecules · doi:10.3390/molecules25225319 · Cited by 141
Mechanisms of Aquaporin-Facilitated Cancer Invasion and Metastasis
Ieso, M. L. D., & Yool, A. J. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00135 · Cited by 111
“…Fushimi et al., 1993; Hasegawa et al., 1994; Raina et al., 1995; Ma et al., 1996, 1997a; Chandy et al., 1997; Ishibashi et al., 1997b; Yasui et al., 1999; Anthony et al., 2000; Nakhoul et al., 2001; Bienert et al., 2007; Herrera and Garvin, 2011; Almasalmeh et al., 2014; Rodrigues et al., 2016).”
Smith, M. L., Murphy, K., Doucette, C. D., Greenshields, A. L., & Hoskin, D. W. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25490 · Cited by 96
“Moreover, breast cancer patients undergoing chemotherapy run the risk of experiencing treatment-limiting sequelae such as cardiovascular toxicity and neuropathy [Guo and Wong, 2014; Rivera and Cianfrocca, 2015].”
BackgroundSynthesis and Evaluation of Paclitaxel-Loaded Gold Nanoparticles for Tumor-Targeted Drug Delivery
Paciotti, G. F., Zhao, J., Cao, S., Brodie, P. J., Tamarkin, L., Huhta, M. S., Myer, L. D., Friedman, J., & Kingston, D. G. I. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00405 · Cited by 93
Song, S. J., Min, J., Suh, S. Y., Jung, S. H., Hahn, H. J., Im, S., & Lee, J. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3631-x · Cited by 87
Tsuyuki, S., Senda, N., Kang, Y., Yamaguchi, A., Yoshibayashi, H., Kikawa, Y., Katakami, N., Kato, H., Hashimoto, T., Okuno, T., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3977-7 · Cited by 86
Salehifar, E., Janbabaei, G., Hendouei, N., Alipour, A., Tabrizi, N., & Avan, R. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-019-00882-6 · Cited by 81
Taxane and epothilone‐induced peripheral neurotoxicity: From pathogenesis to treatment
Tamburin, S., Park, S. B., Alberti, P., Demichelis, C., Schenone, A. E., & Argyriou, A. A. (2019) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12336 · Cited by 76
“In total, data on TIPN severity are quite variable across studies, but up to 20% of patients in clinical trials may demonstrate grade 2 or 3 according to the National Cancer Institute Common Terminology Criteria scale.(48) A single case of fatal acute motor axonal neuropathy resembling Guillain-Barré syndrome, unrespo…”
BackgroundChida, T., Miura, Y., Cabral, H., Nomoto, T., Kataoka, K., & Nishiyama, N. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.035 · Cited by 72
Nascimento, A. V., Gattacceca, F., Singh, A., Bousbaa, H., Ferreira, D., Sarmento, B. F. C. C., & Amiji, M. M. (2016) · Nanomedicine · doi:10.2217/nnm.16.14 · Cited by 61
Substances of Natural Origin in Medicine: Plants vs. Cancer
Gielecińska, A., Kciuk, M., Mujwar, S., Çelik, İ., Kołat, D., Kałuzińska‐Kołat, Ż., & Kontek, R. (2023) · Cells · doi:10.3390/cells12070986 · Cited by 84
“The generation of nab-paclitaxel, a nanoparticle drug bound to albumin, allowed increases in drug solubility and reduction of post-therapy neuropathy symptoms [71].”
BackgroundLococo, P. M., Risinger, A. L., Smith, H. R., Chavera, T. S., Berg, K. A., & Clarke, W. P. (2017) · eLife · doi:10.7554/elife.29626 · Cited by 53
“The microtubule stabilizer, paclitaxel (PTX), is widely used for the treatment of breast, ovarian, lung, and pancreatic cancer (Rivera and Cianfrocca, 2015).”
Backgroundda Costa, R., Bicca, M. A., Manjavachi, M. N., Segat, G. C., Dias, F. C., Fernandes, E. S., & Calixto, J. Β. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0475-9 · Cited by 56
Pereira, S., Fontes, F., Sonin, T., Dias, T., Fragoso, M., Castro‐Lopes, J. M., & Lunet, N. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2935-y · Cited by 57
Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy
Komatsu, M., Wheeler, H. E., Chung, S., Low, S., Wing, C., Delaney, S. M., Gorsic, L. K., Takahashi, A., Kubo, M., Kroetz, D. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0133 · Cited by 49
“Evidence suggests that age, race, and comorbid conditions, such as diabetes, and cumulative dose of drug administered may be associated with an increased risk of developing neuropathy (48).”
BackgroundKim, H. K., Lee, S. Y., Koike, N., Kim, E., Wirianto, M., Burish, M. J., Yagita, K., Lee, H. K., Chen, Z., Chung, J. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-70757-w · Cited by 56
Kim, H. K., Hwang, S.-H., & Abdi, S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00532 · Cited by 51
“This neuropathy can significantly decrease the overall quality of life in cancer patients (Mols et al., 2014; Rivera and Cianfrocca, 2015).”
BackgroundHwang, D., Vinod, N., Skoczen, S. L., Ramsey, J. D., Snapp, K. S., Montgomery, S. A., Wang, M., Lim, C., Frank, J. E., Sokolsky‐Papkov, M., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121140 · Cited by 45
Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug
Brunetti, J., Pillozzi, S., Falciani, C., Depau, L., Tenori, E., Scali, S., Lozzi, L., Pini, A., Arcangeli, A., Menichetti, S., et al. (2015) · Scientific Reports · doi:10.1038/srep17736 · Cited by 40
Foglietta, F., Spagnoli, G. C., Muraro, M. G., Ballestri, M., Guerrini, A., Ferroni, C., Aluigi, A., Sotgiu, G., & Varchi, G. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s159942 · Cited by 43
Kramer, L. (2020) · ALTEX · doi:10.14573/altex.2001181 · Cited by 43
“In some patients, these symptoms resolve following discontinuation of therapy, but an estimated 30% of patients are left with permanent symptoms that affect their overall quality of life (Rivera and Cianfrocca, 2015).”
BackgroundKuş, T., Aktaş, G., Kalender, M., Sevinç, A., Kul, S., Süner, A., Ulker, E., & Camcı, C. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2898-z · Cited by 37
Mosher, C. E., Tometich, D. B., Hirsh, A., Rand, K. L., Johns, S. A., Matthias, M. S., Outcalt, S. D., Bricker, J., Schneider, B., Mina, L., et al. (2017) · Psycho-Oncology · doi:10.1002/pon.4283 · Cited by 34
Valente, S. A., & Roesch, E. E. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27627 · Cited by 52
“37 Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, which is used to treat depression, anxiety, fibromyalgia, and chronic muscle and bone pain, has been shown to improve taxane ‐ induced neuropathy symptoms.”
Singh, R., Adhya, P., & Sharma, S. S. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1956464 · Cited by 34
“the incidence of neuropathy at a cumulative dose of 600 mg/ m(2) or above in humans [30,38], however, neuropathy in rats is”
BackgroundRisinger, A. L., & Du, L. (2019) · Natural Product Reports · doi:10.1039/c9np00053d · Cited by 32
Vergote, I. B., Bergfeldt, K., Franquet, A., Lisyanskaya, A. S., Bjermo, H., Heldring, N., Buyse, M. E., & Brize, A. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.034 · Cited by 32
Nevins, S., McLoughlin, C. D., Oliveros, A., Stein, J. B., Rashid, M. A., Hou, Y., Jang, M., & Lee, K. (2023) · Small · doi:10.1002/smll.202300744 · Cited by 38
Palumbo, R., Sottotetti, F., & Bernardo, A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016639873 · Cited by 32
“2014; Rivera and Cianfrocca, 2015].”
BackgroundFalah, M., Rayan, M., & Rayan, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194965 · Cited by 29
“Although PTX is still used in clinics to treat a variety of tumors [15–19], its use is associated with serious reactive oxygen species generation [20] and other common side effects, such as neutropenia—the most important reversible hematologic toxicity, which is dose and schedule-dependent, and neuropathy that often p…”
BackgroundGordon, M. S., Shapiro, G. I., Sarantopoulos, J., Juric, D., Lu, B., Zarotiadou, A., Connarn, J. N., Bruchec, Y. L., Dumitru, C. D., & Harvey, R. D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.786120 · Cited by 28
“Neutropenia 4 (20) Grade 3/4 (≥ 10%) Patients with any grade 3/4 TEAE 14 (70) Peripheral neuropathy 5 (25) Anemia 3 (15) Dehydration 2 (10) Hypophosphatemia 2 (10)”
BackgroundInfluentialJivani, A., & Shinde, R. K. (2024) · Cureus · doi:10.7759/cureus.59266 · Cited by 25
Attari, F., Keighobadi, F., Abdollahi, M. R., Arefian, E., Lotfizadeh, R., Sepehri, H., & Farimani, M. M. (2020) · Phytotherapy Research · doi:10.1002/ptr.6940 · Cited by 28
“Although conventional treatments, such as chemotherapy, are currently being employed for cancer therapy, they have serious adverse effects on healthy tissues and still encounter drug resistance (Rivera & Cianfrocca, 2015).”
BackgroundRugo, H. S., Umanzor, G. A., Barrios, F., Vasallo, R. H., Chivalan, M., Bejarano, S., Ramirez, J. R., Fein, L. E., Kowalyszyn, R. D., Kramer, E. D., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02953 · Cited by 25
Chua, K. C., El‐Haj, N., Priotti, J., & Kroetz, D. L. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13654 · Cited by 32
“For example, docetaxel and the liposomal formulation of paclitaxel (nabpaclitaxel) are less neurotoxic than paclitaxel.(3,4,6,7) The onset and severity of symptoms are drug-specific but, in general, dependent on the frequency of dose, route of administration, and cumulative dose.”
BackgroundLu, Z., Moody, J. P., Marx, B. L., & Hammerstrom, T. (2017) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2017.0052 · Cited by 26
“Given the prevalence of breast cancer in developed countries,(32) this is not necessarily surprising and likely reflects that patients undergoing taxane-based chemotherapy typically report higher incidences of CIPN as well.(33,34) Furthermore, a 2014 survey assessing the willingness of 300 breast cancer patients to pa…”
Complications from pharmacotherapy
Nabors, B., Surboeck, B., & Grisold, W. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00014-1 · Cited by 23
Anandavadivelan, P., Mijwel, S., Wiklander, M., Kjoe, P. R. L. M., Luijendijk, M. J., Bergh, J. C. S., Rundqvist, H., & Wengström, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-65436-z · Cited by 30
“Taxane-based therapy is now crucial in treating early-stage and advanced cancers, including breast carcinoma, and has led to increased survival rates 36 .”
BackgroundKotani, H., Terada, M., Mori, M., Horisawa, N., Sugino, K., Kataoka, A., Adachi, Y., Gondou, N., Yoshimura, A., Hattori, M., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08240-6 · Cited by 21
“con rmed the effectiveness of compression therapy in preventing CIPN with nab-PTX; in their study, the incidence of grade ≥ 2 PN ranged from 45%–76%, which is higher than the incidence with PTX [16-19].”
BackgroundTumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment
Vergote, I. B., Macarulla, T. M., Hirsch, F. R., Hagemann, C., & Miller, D. S. (2023) · Cancers · doi:10.3390/cancers15030636 · Cited by 24
Integrative Approaches to Chemotherapy-Induced Peripheral Neuropathy
Samuels, N., & Ben‐Arye, E. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0891-2 · Cited by 22
Lodewijckx, J., Robijns, J., Bensadoun, R., & Mebis, J. (2020) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1089/photob.2019.4771 · Cited by 22
“4,20 Photobiomodulation therapy Low-level laser therapy or photobiomodulation therapy (PBMT) was discovered in 1967 by Endre Mester.”
An empirical study on quality of life and related factors of Pakistani breast cancer survivors
Azam, M., Aslam, M., Basharat, J., Mughal, M. A., Nadeem, M. S., & Anwar, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-03696-9 · Cited by 27
Cho, I. R., Kang, H., Jo, J. H., Lee, H. S., Chung, M. J., Park, J. Y., Park, S. W., Song, S. Y., Chung, J. B., An, C., et al. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.01.001 · Cited by 19
Adra, J., Giglio, D., Karlsson, P., Zetterberg, H., & Einbeigi, Z. (2024) · Acta Oncologica · doi:10.2340/1651-226x.2024.39895 · Cited by 19
“Studies in patients with metastatic breast cancer show that CIPN induced by taxanes occurred in 4%–30% of cases, where the dose and dose interval of paclitaxel correlated with the severity of CIPN [5].”
BackgroundNaguib, Y. W., Alhaj-Suliman, S. O., Wafa, E. I., Saha, S., Ebeid, K., Hashem, H., Abdel‐Rahman, S. A., Abuo‐Rahma, G. E. A., Geary, S. M., & Salem, A. K. (2023) · Small · doi:10.1002/smll.202302931 · Cited by 21
Kırca, K., & Kutlutürkan, S. (2018) · European Journal of Breast Health · doi:10.5152/ejbh.2018.3785 · Cited by 23
Ronconi, G., Gatto, D. M., Codazza, S., Ariani, M., Martire, E., Cerretti, L., Carella, V., Coraci, D., Ferriero, G., & Ferrara, P. E. (2024) · European Journal of Physical and Rehabilitation Medicine · doi:10.23736/s1973-9087.24.08197-8 · Cited by 22
Rattanakrong, N., Siriphorn, A., & Boonyong, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-14870-y · Cited by 19
Kruse, F. L., Bille, M. B., Lendorf, M. E., Vaabengaard, S., & Birk, S. (2025) · Acta Oncologica · doi:10.2340/1651-226x.2025.42109 · Cited by 15
Spera, M. C., Cesta, M. C., Zippoli, M., Varrassi, G., & Allegretti, M. (2022) · Pain and Therapy · doi:10.1007/s40122-022-00431-8 · Cited by 15
Lahsaee, S., Corkery, D., Anthes, L. E., Holly, A. C., & Dellaire, G. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.12.013 · Cited by 17
Moradi, M., Gholipour, H., Sepehri, H., Attari, F., Delphi, L., Arefian, E., & Farimani, M. M. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01917-y · Cited by 18
Chahal, S. K., Sodhi, R. K., & Madan, J. (2020) · IBRO Reports · doi:10.1016/j.ibror.2020.07.006 · Cited by 16
“Paclitaxel (Taxol) is a taxane-based drug commonly used for the treatment of various solid tumors such as breast, lung or ovarian cancer (Rivera and Cianfrocca, 2015; Dougherty et al., 2004).”
BackgroundA Bibliometric Review of Publications on Oxidative Stress and Chemobrain: 1990–2019
McElroy, T., & Allen, A. R. (2020) · Antioxidants · doi:10.3390/antiox9050439 · Cited by 15
“Paclitaxel has been associated with neuropathy which can persist after treatment [30].”
BackgroundKlein, I., Wiesen, M. H. J., Albert, V., Bobylev, I., Joshi, A. R., Müller, C., & Lehmann, H. C. (2021) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12440 · Cited by 14
“For instance, in patients with metastatic breast cancer, 3-weekly administrations of paclitaxel in doses of 175 mg/m(2) evokes a neuropathy (grade 1-4) in 57% of patients, compared to 82% when a dose of 250 mg/m(2) was used.(1,4) Neurotoxicity is thus the most relevant dose-limiting factor of paclitaxel with a discont…”
BackgroundAlsharedi, M. F., Gress, T., Dotson, J., Elmsherghi, N., & Tirona, M. T. (2016) · Medical Oncology · doi:10.1007/s12032-016-0740-1 · Cited by 13
“However, the development of paclitaxel-related toxicities, which include chemotherapy-induced peripheral neuropathy (CIPN) [3]; hematologic toxicities, particularly neutropenia; fatigue and musculoskeletal symptoms [18]; allergic reactions, gastrointestinal symptoms, and to a less extent, alopecia [4, 5], has led to e…”
BackgroundInfluentialGuo, Q., Zhang, H., Li, X., & Quan, X. (2022) · BioMed Research International · doi:10.1155/2022/9430952 · Cited by 14
Xing, H., Zhang, S., You, M., Yan, M., Zhang, J., Chen, J., Chen, Y., Liu, X., & Zhu, J. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00411 · Cited by 13
Marschner, N. W., Salat, C., Söling, U., Hansen, R., Grebhardt, S., Harde, J., Nusch, A., & Potthoff, K. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.010 · Cited by 13
Mohammadzadeh, M., Hacımüftüoğlu, A., Taghizadehghalehjoughi, A., Taşpınar, N., Toğar, B., Nalcı, K. A., Okkay, U., & Gündoğdu, B. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1455_16 · Cited by 15
Kida, K., Yamada, A., Shimada, K., Narui, K., Sugae, S., Shimizu, D., Doi, T., Oba, M. S., Endo, I., & Ishikawa, T. (2024) · Breast Cancer · doi:10.1007/s12282-024-01551-z · Cited by 12
Fall Risk Associated with Taxanes: Focus on Chemotherapy-Induced Peripheral Neuropathy
Visovsky, C. M., Teran-Wodzinski, P. C., Haladay, D. E., Ji, M., & Coury, J. (2024) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2024.151687 · Cited by 15
Teran-Wodzinski, P. C., Haladay, D. E., Vu, T., Ji, M., Coury, J., Adams, A., Schwab, L., & Visovsky, C. M. (2022) · Trials · doi:10.1186/s13063-022-06294-w · Cited by 14
“The treatment of invasive breast cancer will require a chemotherapy regimen that includes taxanes as a standard treatment for invasive breast cancer [1].”
BackgroundEvaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer
Luca, A. D., D’Alessio, A., Maiello, M. R., Gallo, M., Chicchinelli, N., Pergameno, M., Piccirilli, M. S., & Normanno, N. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1057497 · Cited by 12
“These data are consistent with reported data of grade 3 neuropathy observed in taxanes-treated patients [54].”
ResultChen, Y., Fang, F., Kidwell, K., Vangipuram, K., Marcath, L. A., Gersch, C. L., Rae, J. M., Hayes, D. F., Smith, E., Henry, N. L., et al. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0053 · Cited by 12
“Discussion PN is a common, debilitating, sometimes irreversible side effect of paclitaxel treatment [5,8,43].”
BackgroundAntibody-drug conjugates in solid tumors; new strategy for cancer therapy
Takakura, T., Shimizu, T., & Yamamoto, N. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae054 · Cited by 13
“Limiting the treatment duration is widely adopted when using taxanes or platinum salts to minimise chronic toxicities such as peripheral neuropathy (52,53).”
BackgroundMechanistic insights into chemotherapy-induced circadian disruption using rodent models
Tapp, Z. M., Ghosh, A. K., Obrietan, K. H., & Pyter, L. M. (2025) · Trends in Neurosciences · doi:10.1016/j.tins.2024.12.011 · Cited by 10
Sharma, A., Johnson, K. B., Bie, B., Rhoades, E. E., Sen, A., Kida, Y., Hockings, J. K., Gatta, A., Davenport, J., Arcangelini, C., et al. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221127169 · Cited by 11
“However, taxanes are known to produce severe neuropathic pain (TIPN) which is also one of the primary dose-limiting toxicities.(2,4) A meta-analysis reported that the TIPN prevalence with paclitaxel was 70.”
BackgroundMatsuo, M., Ito, H., Takemura, Y., Hattori, M., Kawakami, M., Takahashi, N., & Yamazaki, M. (2017) · Journal of Anesthesia · doi:10.1007/s00540-017-2362-y · Cited by 10
“Clinical research with paclitaxel has shown grade 3–4 neuropathy rates ranging from 2 to 8%, as graded by the Common Terminology Criteria Adverse Events (CTCAE) system [2, 3].”
MethodMehrotra, S., Sharma, M. R., Gray, E., Wu, K., Barry, W. T., Hudis, C. A., Winer, E. P., Lyss, A. P., Toppmeyer, D., Moreno‐Aspitia, A., et al. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0101-9 · Cited by 10
“The authors attributed the higher rate of CIPN with nab-paclitaxel to a 49% higher actual delivered paclitaxel dose for nab-paclitaxel as compared to paclitaxel (12).”
Yuan, F., Qiao, L., Chen, Y., Qi, X., Liu, Y., Li, D., Gu, Q., Li, J., & Liu, M. (2017) · Marine Drugs · doi:10.3390/md15110346 · Cited by 10
You, M. S., Ryu, J. K., Choi, Y. H., Choi, J. H., Huh, G., Paik, W. H., Lee, S. H., & Kim, Y. (2018) · Gut and Liver · doi:10.5009/gnl18220 · Cited by 10
Correlates of Taxane-Induced Neuropathy, an Electronic Health Record Based Observational Study
Dorand, R. D., Zheng, N. S., Agarwal, R., Carroll, R. J., Rubinstein, S. M., Winkfield, K. M., Wei, W., Berlin, J. D., & Shu, X. (2023) · Cancers · doi:10.3390/cancers15030754 · Cited by 10
“Treatment characteristics, including mean taxane dose and number of cycles, had a positive association with the development of CIPN, as reported elsewhere [7].”
BackgroundBimodal Imaging of Mouse Peripheral Nerves with Chlorin Tracers
Gonzales, J., Hernández‐Gil, J., Wilson, T. C., Adilbay, D., Cornejo, M., França, P. D. D. S., Guru, N., Schroeder, C. I., King, G. F., Lewis, J. S., et al. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00946 · Cited by 9
Kawahara, T., Shimozuma, K., Shiroiwa, T., Hagiwara, Y., Uemura, Y., Watanabe, T., Taira, N., Fukuda, T., Ohashi, Y., & Mukai, H. (2017) · Oncology · doi:10.1159/000484142 · Cited by 9
The motivation of breast cancer patients to participate in a national randomized control trial
Wegge-Larsen, C., Mehlsen, M. Y., & Jensen, A. B. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07930-0 · Cited by 8
Li, X., Gao, B., & Su, X. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8902 · Cited by 11
Catalano, M., Aprile, G., Ramello, M., Conca, R., Petrioli, R., & Roviello, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091846 · Cited by 8
Yegdaneh, A., Saeedi, A., Shahmiveh, T., & Vaseghi, G. (2020) · Advanced Biomedical Research · doi:10.4103/abr.abr_183_20 · Cited by 8
“It has been shown that inhibition of complex III, a mitochondrial reactive oxygen species producing site, increased antinociceptive effects on the development and maintenance of paclitaxel‐induced pain.[2]”
BackgroundRattanakrong, N., Promma, N., Saraboon, C., & Waongenngarm, P. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-06927-5 · Cited by 10
“Chemotherapy agents, especially taxane and platinum compounds, are associated with a high prevalence of CIPN symptoms, ranging from 71 to 83% [3, 4].”
BackgroundNeurotoxicity induced by taxane-derived drugs: analysis of the FAERS database 2017–2021
Jiaying, Z., Luo, L., Long, E., & Chen, L. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2193391 · Cited by 8
“Our findings based on real-world neurological adverse effect onset time are considered valuable to clinicians when considering the timing, choice, and dose/schedule of later therapy [51].”
BackgroundNutritional Modulators in Chemotherapy-Induced Neuropathic Pain
Alexa‐Stratulat, T., Luca, A., Bădescu, M., Bohotin, C. R., & Alexa, I. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805186-3.00002-3 · Cited by 10
Harano, K., Fossati, R., Pardo, B., Galli, F., Hudson, E., Antill, Y. C., Lee, C., Rabaglio, M., Heitz, F., Kolovetsiou-Kreiner, V., et al. (2025) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2025.36.e117 · Cited by 39
Chemotherapy-induced peripheral neurotoxicity: single-centre prospective study
Kridis, W. B., Toumi, N., & Khanfir, A. (2023) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2023-004332 · Cited by 6
Yu, B., Tian, X., Zhang, L., & Feng, R. (2016) · DNA and Cell Biology · doi:10.1089/dna.2016.3318 · Cited by 6
“However, severe side effects such as neuropathies and primary or acquired resistance in some patients limit the clinical utilization of paclitaxel (Rivera and Cianfrocca, 2015).”
Metadata
- Authors
- Rivera, E., & Cianfrocca, M.
- Affiliations
- Banner MD Anderson Cancer Center (US)
- Corresponding author
- Rivera, Edgardo
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2015-01-18
- Volume
- 75
- Issue
- 4
- Pages
- 659-670
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- PMC
- PMC4365177
- OpenAlex
- W2061239263
- Cited by
- 159
- References
- 89
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 11 · 2023: 14 · 2022: 19 · 2021: 15 · 2020: 19 · 2019: 7 · 2018: 14 · 2017: 16 · 2016: 14 · 2015: 8
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Celgene
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- taxanes, neuropathy, metastatic breast cancer, nab-paclitaxel, paclitaxel, docetaxel, chemotherapy toxicity, dose-limiting toxicity, patient-reported outcomes, quality of life
- MeSH terms
- Antineoplastic Agents, Breast Neoplasms, Clinical Trials as Topic, Drug Administration Schedule, Female, Humans, Neoplasm Metastasis, Neuralgia, Taxoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.